Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?

Moderna posted a narrower per-share loss in its latest quarter, but shares traded slightly lower as the company’s earnings report highlighted the drugmaker’s ongoing struggle to break away from its pandemic-driven business model. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.